Examples of using Labelling and package leaflet in English and their translations into Portuguese
{-}
- 
                        Medicine
                    
 - 
                        Colloquial
                    
 - 
                        Official
                    
 - 
                        Financial
                    
 - 
                        Ecclesiastic
                    
 - 
                        Ecclesiastic
                    
 - 
                        Computer
                    
 - 
                        Official/political
                    
 
For harmonised labelling and package leaflet.
The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III.
SmPC, labelling and package leaflet should reflect the presence of a score.
Chapter 4 summary of product characteristics, labelling and package leaflet.
The SPC, labelling and package leaflet proposed by the applicant has been assessed based on.
The Summary of Products Characteristic, labelling and package leaflet proposed by the.
The SPC, labelling and package leaflet proposed by the applicant has been assessed based on the.
The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing.
Therefore the PRAC considered that this information should be added to the relevant sections of the SmPC, labelling and package leaflet.
Proposal for a Council directive on the labelling and package leaflet of medicinal products for human consumption.
Grounds for amendments of the Summaries of Products Characteristics, labelling and Package leaflet.
Therefore, this SPC, labelling and package leaflet may not necessarily represent the current text.
The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III.
The draft text of the labelling and package leaflet proposed by the applicant, presented in accordance with Title V of Directive 2001/83/EC;
The revised Product Information(Summary of Product Characteristics, Labelling and Package Leaflet) is set out in Annex II of the Opinion.
The draft text of the labelling and package leaflet proposed by the applicant, presented in accordance with Directive 92/27/EEC, without prejudice to the provisions of Article 7(2) of that Directive;
The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
The scientific conclusions are provided in Annex II,together with the Summary of Product Characteristics, labelling and package leaflet in Annex III.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
The CHMP gave a positive opinion on 22 February 2007 recommending the harmonisation of the SPC, labelling and package leaflet for Xefo and  associated names.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination Group procedure with the following amendment.
The CHMP gave a positive opinion on 26 June 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet including quality aspects for Gemzar.
The Summary of Product Characteristics, labelling and package leaflet are set out in Annex III of the opinion for Glucomedand  associated names see Annex I.
The CHMP gave a positive opinion on 30 May 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Zyrtec and  associated names.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure as mentioned in Annex III.
The CHMP gave a positive opinion on 1 June 2006 recommending the harmonisation of the SPC, labelling and package leaflet for Neurontin and  associated names.
This Annex III(Summary of Product Characteristics, Labelling and Package Leaflet) is the one that was Annexed to the Commission Decision on this Article 6(13) referral for Seretide Evohaler and  associated names.
The CHMP gave a positive opinion on 24 July 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Risperdal and  associated names.
After receipt of a valid application it is the duty of the reference Member State to prepare, within 120 days, a draft assessment report,a draft summary of products characteristics and  a draft of the labelling and package leaflet.